Interpretation of the NCCN clinical practice guidelines in oncology for non-small cell lung cancer (version 2.2023)
- VernacularTitle:2023年第二版《NCCN肿瘤临床实践指南： 非小细胞肺癌》更新解读
- Author:
Wenjie WANG
1
;
Chenzhen XU
1
;
Minglang GAO
1
;
Yi YAO
2
;
Qing GENG
1
Author Information
1. Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, P. R. China
2. Cancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, P. R. China
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
NCCN guideline;
guideline interpretation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(05):660-664
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the malignancy with the highest incidence and mortality rate in China. In recent years, the popular use of low-dose computed tomography in the population has led to an increase in the detection rate of pulmonary nodules. The National Comprehensive Cancer Network (NCCN) updated and released the NCCN clinical practice guidelines in oncology for non-small cell lung cancer (version 2.2023) on February 17, 2023. This article will interpret the main updates of the new guideline and compare it with the domestic lung cancer treatment guidelines, providing new ideas for the diagnosis and treatment of lung cancer for Chinese clinicians.
